Xencor (XNCR) Capital Expenditures (2013 - 2026)
Xencor (XNCR) posted quarterly Capital Expenditures of $610000.0 for Q1 2026, down 57.76% year-over-year from $1.4 million in Q1 2025, and down 46.49% quarter-over-quarter from $1.1 million in Q4 2025.
Analysis
Xencor (XNCR) Capital Expenditures (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Capital Expenditures for 14 consecutive years, with $610000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 57.76% year-over-year to $610000.0; the TTM figure through Mar 2026 stood at $2.3 million (down 68.74% YoY), while the FY2025 annual figure was $3.2 million, down 48.34% from the prior year.
- Capital Expenditures fell to $610000.0 in Q1 2026 per XNCR's latest filing, from $1.1 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $14.1 million in Q3 2022 and bottomed at $132000.0 in Q1 2024.
- Historically, Capital Expenditures has averaged $3.9 million across 5 years, with a median of $1.7 million in 2024.
- Annual changes were most pronounced in 2024 — Capital Expenditures slumped 98.78% — and 2025, when it jumped 993.94%.
- Xencor's Capital Expenditures stood at $10.0 million in 2022, then plunged by 90.17% to $980000.0 in 2023, then surged by 69.8% to $1.7 million in 2024, then tumbled by 31.49% to $1.1 million in 2025, then plunged by 46.49% to $610000.0 in 2026.
- Business Quant data shows XNCR's Capital Expenditures at $610000.0 in Q1 2026, $1.1 million in Q4 2025, and $183000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 538,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 538,000.00 |
| Mar 31, 2026 | 610,000.00 |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 183,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 132,000.00 |
| Dec 31, 2023 | 980,000.00 |
| Sep 30, 2023 | 2.83 Mn |
| Jun 30, 2023 | 3.85 Mn |
| Mar 31, 2023 | 10.78 Mn |
| Dec 31, 2022 | 9.97 Mn |
| Sep 30, 2022 | 14.09 Mn |
| Jun 30, 2022 | 12.35 Mn |
| Mar 31, 2022 | 2.09 Mn |
| Dec 31, 2021 | 6.32 Mn |
| Sep 30, 2021 | 2.75 Mn |